Crestline Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Crestline Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-63,125	Closed	-$758K	–	199
2018 Q2	$758K	Buy	+63,125	New	+$646K	0.08%	212

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Crestline Management's LXRX Position: Q3 2018 in Review

Crestline Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2018, closing a stake of 63,125 shares — an estimated $758K sold.

Crestline Management first reported a position in LXRX in Q2 2018 and held it in 1 quarter. The position peaked at $758K in Q2 2018. 119 funds tracked by Wall St. Rank hold LXRX as of Q3 2018.

Crestline Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Crestline Management sold 63,125 Lexicon Pharmaceuticals shares in Q3 2018, an estimated $758K.
Crestline Management first reported a position in Lexicon Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Crestline Management's Lexicon Pharmaceuticals position peaked at $758K in Q2 2018.
119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.